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Abstract
Clinical analysis of blood is the most widespread diagnostic proce-
dure in medicine, and blood biomarkers are used to categorize
patients and to support treatment decisions. However, existing
biomarkers are far from comprehensive and often lack specificity
and new ones are being developed at a very slow rate. As described
in this review, mass spectrometry (MS)-based proteomics has
become a powerful technology in biological research and it is now
poised to allow the characterization of the plasma proteome in
great depth. Previous “triangular strategies” aimed at discovering
single biomarker candidates in small cohorts, followed by classical
immunoassays in much larger validation cohorts. We propose a
“rectangular” plasma proteome profiling strategy, in which the
proteome patterns of large cohorts are correlated with their
phenotypes in health and disease. Translating such concepts into
clinical practice will require restructuring several aspects of diag-
nostic decision-making, and we discuss some first steps in this
direction.
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Introduction
The central and integrating role of blood in human physiology
implies that it should be a universal reflection of an individual’s
state or phenotype. Its cellular components are erythrocytes, throm-
bocytes, and lymphocytes. The liquid portion is called plasma,
when all components are retained, and serum, when the coagula-
tion cascade has been activated (blood clotting). For simplicity, we
will use the term “plasma” rather than “serum”, since most conclu-
sions apply to both.
Concentrations of various plasma components are routinely
determined in clinical practice. These include electrolytes, small
molecules, drugs, and proteins. The proteins constituting the plasma
proteome can be categorized into three different classes (Fig 1A and
B). The first contains abundant proteins with a functional role in
blood. These include human serum albumin (HSA, roughly half of
total protein mass); apolipoproteins, which have crucial roles in
lipid transport and homeostasis; acute phase proteins of the innate
immune response; and proteins of the coagulation cascade. The
second class are tissue leakage proteins without a dedicated func-
tion in the circulation. Examples are enzymes such as aspartate
aminotransferase (ASAT) and alanine aminotransferase (ALAT),
which are used for the diagnosis of liver diseases, as well as low-
level, tissue-specific isoforms of proteins such as cardiac troponins.
The third class are signaling molecules like small protein hormones
(for instance, insulin) and cytokines, which typically have very low
abundances at steady state and are upregulated when needed.
Baseline levels of the cytokine interleukin-6 (IL-6) are 5 pg/ml,
establishing a minimum 1010-fold dynamic range of the plasma
proteome when compared to the concentration of the most
abundant protein, HSA, with about 50 mg/ml.
In accepted use, “a biomarker is a defined characteristic that is
measured as an indicator of normal biological processes, patho-
genic processes, or a response to an exposure or intervention”
(FDA-NIH: Biomarker-Working-Group, 2016). For the purpose of
this review, we focus specifically on protein or protein modifi-
cation-based biomarkers. In this sense, there are more than 100
FDA-cleared or FDA-approved clinical plasma or serum tests,
mainly in the abundant, functional class (50%), followed by tissue
leakage markers (25%), and the rest include receptor ligands,
immunoglobulins, and aberrant secretions (Anderson, 2010). Most
of these are decades old, and the current introduction rate of
novel markers is less than two per year (Anderson et al, 2013). A
typical test consists of an enzymatic assay or immunoassay against
a single target. Clinicians interpret the results in conjunction with
other patient information, based on their expert knowledge. Ratios
of abundances are only employed in specific cases. Examples are
the 60-year-old De Ritis ratio of ASAT/ALAT to differentiate
between causes of liver disease (De-Ritis et al, 1957) or the more
recent sFlt-1/PlGF ratio for diagnosis of preeclampsia (Levine et al,
2004).
In contrast to enzymatic and antibody-based methods, mass
spectrometry (MS)-based proteomics measures the highly accurate
mass and fragmentation spectra of peptides derived from sequence-
specific digestion of proteins. Because the masses and sequences of
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these peptides are unique, proteomics is inherently specific, a
constant problem with colorimetric enzyme tests and immuno-
assays (Wild, 2013). In principle, MS-based proteomics can analyze
all the proteins in a system—its proteome—and is in this sense
unbiased and hypothesis-free (Aebersold & Mann, 2016). Further-
more, MS methods are ideally suited to discover and quantify post-
translational modifications (PTMs) on proteins. These PTMs can
also be the basis of diagnostic tests, such as HbA1c levels that serve
as a readout of long-term glucose exposure in the context of
diabetes. Nevertheless, none of the routinely performed laboratory
tests in plasma is based on proteins that were identified by mass-
spectrometric approaches, and in routine analysis, MS is so far only
employed for measuring small molecules such as drugs and metabo-
lites (Vogeser & Seger, 2016).
Over the past years, the technology of MS-based proteomics
has dramatically improved, and it is now a mainstay of all biolog-
ical research that involves proteins (Cox & Mann, 2011; Altelaar
& Heck, 2012; Richards et al, 2015; Zhang et al, 2016). In
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Figure 1. Blood-based laboratory testing in a clinical setting.
(A) Concentration range of plasma proteins with the gene names of several illustrative blood proteins (red dots). Concentrations are in serum or plasma and measured with
diverse methods as retrieved from the plasma proteome database in May 2017 (http://www.plasmaproteomedatabase.org/) (Nanjappa et al, 2014). (B) Bioinformatic keyword
annotation of the plasma proteome database. The blue boxplots with the 10–90% whiskers visualize the range of diverse proteins contributing to distinct functions. (C)
Percentage of inpatient admissions receiving blood-based laboratory testing. Numbers are based on 9 million tests performed in the year 2016 at the Institute of Laboratory
Medicine, University Hospital Munich. (D) Percentage of outpatient admissions receiving blood-based laboratory testing. (E) Distribution of laboratory tests based on
frequency of request. Examples of test for different classes of analytes are as follows: Proteins and enzymes—liver enzymes, inflammatory proteins, tumor markers; Small
molecules—electrolytes, substrates, vitamins; Cells—red, white blood cells, and platelets; Drugs—immunosuppressants, antibiotics, and drugs of abuse; Specific antibodies—
autoantibodies and antibodies against infectious agents; and Nucleic acids—viruses and genetic variants.
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particular, its performance has robustly matured into a sensitivity
and dynamic range that makes it interesting for biomarker stud-
ies. This review will focus on the prospects of determining
proteins in blood by mass spectrometry. We start by empirically
assessing the role of proteins in clinical diagnostic today and
exhaustively review the literature on previous attempts at finding
biomarkers in plasma by MS-based proteomics. So far, proteomics
strategies have involved extensive investigations of few samples,
to be followed up by targeted approaches in larger cohorts. We
discuss how recent advances in technology now enable a new
strategy in which deep proteomes are measured for many time
points and participants with the prospect to find new biomarkers
and biomarker panels. We believe that proteomics will become
part of the instrumental routine in the clinical laboratory within
the next decade and may even eliminate current technologies in
the far future.
The current extent of clinical protein-based diagnostics
Laboratory tests of blood and body fluids aim at disease diagnosis
or confirmation, risk prediction, prognosis monitoring, and evaluat-
ing treatment effectiveness. It is commonly assumed that 70% of
diagnoses are informed by blood testing, even though this number
has not been well substantiated. At the Institute of Laboratory
Medicine of the University Hospital Munich, laboratory testing is
ordered for the vast majority of inpatients at some point during
hospitalization (77%; Fig 1C). This fraction is much smaller in
patients seen in one of the Hospital’s outpatient clinics (31%;
Fig 1D). These numbers indicate that hospitalized patients, who are
usually sicker, are more likely to receive laboratory tests than
ambulatory patients. Based on numbers of requested analyses, clini-
cal routine is dominated by proteins (42% of analyses), followed by
small molecules (35%) and cells (17%) (Fig 1E). Thus, already
today proteins are the most frequently assayed class of laboratory
analytes in clinical practice. We also note that methods suitable for
determining plasma proteins have the largest share of the world-
wide in vitro diagnostics.
Laboratory assays for plasma proteins are based either on clas-
sical clinical chemistry, utilizing enzymatic activities of certain
plasma proteins, or on antibody-based immunoassays. The costs
of enzymatic assays are only in the cent-range, and they run on
high-throughput automated analyzers, delivering up to 10,000 test
results per hour. In contrast, immunoassays are more expensive
(usually several euros/dollars per sample) and throughput of the
respective automated analyzers is about 1,000 tests/hour. Large
clinical chemistry as well as immunoassay-based analyzers may
carry reagents for more than 100 different analytical parameters.
Main advantages of immunoassays are a greater degree of flexibil-
ity due to the accessibility to plasma proteins devoid of enzymatic
activity and a significantly higher sensitivity. Another, clinically
relevant issue is the time required per laboratory test. Due to the
necessity of immediate decision-making, the majority of enzy-
matic assays and several immunoassays have to be scaled down
to analysis times of < 10 min. In general, immunoassays tend to
take longer than enzymatic assays; nevertheless, the vast majority
of current automated immunoassays require no more than
30 min.
Systematic review of MS-based plasma proteomics in
biomarker research
Plasma proteins had already been investigated by two-dimensional
gel electrophoresis in the 1990s, sometimes in combination with MS
identification of excised spots. However, these generally identified
only a few dozen proteins, and as they preceded MS-based proteo-
mics, they are not discussed in this review. Claims of early cancer
detection based on very low-resolution MALDI spectra of plasma
that produced patterns but no protein identifications (Petricoin et al,
2002) have not been substantiated (Baggerly et al, 2004), and these
technologies have largely been abandoned today.
To obtain a comprehensive collection of publications dealing
with plasma biomarker research and employing MS-based proteo-
mics, we performed an unrestricted PubMed search specifying co-
occurrence of the terms “biomarker”, “plasma OR serum”,
“proteome”, “proteomics”, and “mass spectrometry”. This yielded
an initial list of 947 publications of which 103 were reviews. We
further subtracted studies that did not deal with human subjects or
did not involve plasma or serum, leaving 381 original publications
(Dataset EV1).
Publications started to appear in 2002 and reached a maximum
of 33 per year in 2005, when the special issue on the plasma
proteome was released by the Human Proteome Organization
(HUPO) (Omenn et al, 2005). Two further maxima appeared in
2011 and 2014 with 39 and 43 publications per year, followed by
drops in 2013 to 24 and in 2016 to only 20 publications per year
(Fig 2A). The observed dynamics contrasts with an ever-expanding
community of researchers using proteomics, which is reflected in
thousands of publications per year, with a clear upward trend. The
ratio of plasma proteome publications to total proteome publications
is now < 1% and continues to drop. Given the clear medical need
for plasma biomarkers and the success of MS-based proteomics in
other areas, this raises the question as to what holds back the field
of plasma proteomics.
Of the 381 primary publications, about half dealt with the analyt-
ical descriptions of the workflow employed in plasma analysis,
whereas the remainder investigated a physiological or pathophysio-
logical question (Fig 2B). About a third of the latter focused on
cancer, followed by cardiovascular disease (CVD), topics in human
biology, inflammation, diabetes, and infectious diseases (Fig 2B).
Clearly, this ordering reflects the interest in the diseases rather than
the likelihood of finding relevant changes with the available tech-
nology. Only 47% of the studies had any kind of validation of the
primary findings (Fig 2C). In half of the cases (24%), these were
simple Western blots or ELISAs of candidate proteins performed
with the same samples rather than an independent cohort as is
usual practice in clinical studies. Only 36 papers used MS-based
proteomics to validate potential biomarkers that were proposed
independently (Dataset EV1).
The extremely high dynamic range of plasma still makes it diffi-
cult to identify more than a few hundred of the most abundant
proteins by LC-MS/MS. To partially overcome this challenge, highly
abundant plasma proteins are often depleted, generally through
columns with immobilized antibodies directed against the top 1 to
20 proteins (Fig 2D). However, these antibodies are never entirely
specific and bound proteins—such as HSA—themselves have an
affinity for several other proteins (Tu et al, 2010; Bellei et al, 2011).
ª 2017 The Authors Molecular Systems Biology 13: 942 | 2017
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Thus, the depleted plasma sample is not a quantitative representa-
tion of the original proteome. This is especially true when using
“super-depletion” (Qian et al, 2008)—a broad mixture of polyclonal
antibodies raised against whole plasma—or beads with hexameric
peptide mixtures that non-specifically “normalize” the plasma
proteome (Thulasiraman et al, 2005). Furthermore, these proce-
dures introduce variability and additional expense into the work-
flow, generally precluding accurate quantification of plasma
proteins. Therefore, their use is currently restricted to small discov-
ery projects.
A second strategy to deal with the dynamic range and sensitivity
challenge is extensive plasma fractionation, which can be done in
various ways at the protein or peptide level. Several studies aiming
at in-depth coverage of the plasma proteome by combined depletion
and extensive separation (up to hundreds of fractions) identified
from several hundred to several thousand proteins (Liu et al, 2006;
Pan et al, 2011; Cao et al, 2012; Cole et al, 2013; Keshishian et al,
2015; Lee et al, 2015). Note that many plasma proteome studies
continue to use much less stringent statistical identification criteria
than the 1% peptide and protein false discovery rates (FDR) that
have become standard in MS-based proteomics.
The decrease in throughput implicit in fractionation can partially
be recovered by multiplexing. For example, between four and ten
samples have been analyzed together using the iTRAQ or TMT
strategies, in which samples are labeled with mass neutral tags that
give rise to different low mass reporter ions (Kolla et al, 2010; Zhou
et al, 2012; Cominetti et al, 2016). Quantification is achieved by
fragmenting peptides and quantifying the relative ratios of the
reporter ions (Bantscheff et al, 2008). Although attractive in princi-
ple, these techniques generally suffer from ratio distortion caused
by co-isolated peptide species that all contribute to the same
reporter ion pattern (“ratio compression”). Regulation of very
low-level proteins or those with small but disease-relevant changes
may be completely obscured. In shotgun proteomics, eluting
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Figure 2. Comprehensive literature review.
(A) Publications using MS-based proteomics in plasma biomarker research (red) compared to the total number of publications in proteomics (blue). (B) Pie charts about
the intentions of the investigated studies and proportions of investigated diseases. (C) Overview of the percentage of studies, using discovery and validation phases. (D) Studies
using pooled samples, depletion, fractionation, and multiplexing in plasma biomarker research using MS-based proteomics.
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peptides are fragmented in order of intensity (data-dependent
acquisition), a semi-stochastic process that may lead to missing
values across LC-MS/MS runs. Recently introduced data-independent
acquisition strategies more consistently identify peptides across runs
(Picotti & Aebersold, 2012; Sajic et al, 2015). However, they are
incompatible with reporter-ion-based multiplexing because one
would quantify the average of groups of peptides.
In about 30% of the studies, plasma samples were pooled to
reach a desired plasma proteome coverage within the available
measuring time. This approach sacrifices within-group variances
and outlier or contaminant proteins in individual samples can skew
the whole group, making it all but impossible to assess whether
proteins that are different between groups are actually significant on
a person-by-person basis.
Partly as a consequence of the demands on instrument time,
generally no more than 20–30 samples were analyzed and only few
exceeded 500 (Garcia-Bailo et al, 2012; Cominetti et al, 2016; Lee
et al, 2017). Considering the large number of measurement points
within samples, these are small sample numbers. Accordingly, most
studies proposed a few “potential biomarkers”, defined as proteins
that differ between cases and controls. Furthermore, many of these
candidates are unlikely to be specific indicators of the disease in
question, because they belong to biological categories that are at
best indirectly related to the disease or are likely artifacts of sample
preparation (such as keratins and red blood cell proteins). In
summary, limitations in proteomics technology and experimental
design have prevented the identification of true biomarkers in the
published literature to date. To our knowledge, the only possible
exception is the OVA1 test, in which the levels of the highly abun-
dant plasma proteins beta-2 macroglobulin, apolipoprotein 1, serum
transferrin, and pre-albumin were combined with the previously
established ovarian cancer marker CA125 in a narrow, FDA-
approved indication (Rai et al, 2002; Zhang et al, 2004).
Triangular MS-based biomarker discovery and
validation strategy
The principal advantage of hypothesis-free MS-based proteomics is
that no assumptions need to be made regarding the possible nature
and number of potential biomarkers, in stark contrast to single
protein measurements in classical biomarker research. Conceptu-
ally, MS-based proteomics combines all possible hypothesis-driven
biomarker studies for each disease into one and furthermore defines
the relation of potential biomarkers to each other. In practice, the
challenges of plasma proteomics have so far prevented in-depth and
quantitative studies on large cohorts. Instead, a stepwise or “trian-
gular” strategy for biomarker discovery has been advocated, with
several phases in which the number of individuals increases from a
few to many, whereas the number of proteins decreases from
hundreds or thousands to just a few (Rifai et al, 2006; Fig 3A).
The typical workflow for hypothesis-free discovery proteomics in
plasma is similar to that used in other areas of bottom-up proteo-
mics (Aebersold & Mann, 2016; Altelaar & Heck, 2012; Fig 3B).
Briefly, proteins are enzymatically digested into peptides, which are
separated by high-pressure liquid chromatography (HPLC) coupled
to electrospray ionization. Peptide masses and abundances are
measured in the mass spectrometer in full MS scans, whereas a
further step of peptide fragmentation produces MS/MS spectra for
peptide identification. Well-established proteomics software plat-
forms automatically and statistically rigorously identify peptides in
database searches and quantify them (Cox & Mann, 2008; MacLean
et al, 2010; Rost et al, 2014). Furthermore, plasma contains blood
components such as lipids that can easily clog HPLC columns,
which necessitates dedicated peptide cleanup procedures (Geyer
et al, 2016a).
Targeted proteomics for candidate verification is a second phase
of the triangular strategy (Fig 3C). A relatively small number of
proteins (typically < 10) with differential expression in the discov-
ery phase are tested in a larger and ideally independent cohort.
Since immunoassays are often not available, targeted MS methods
can be employed. The most widespread of these is “multiple reac-
tion monitoring” (MRM—sometimes also called single or selected
reaction monitoring—SRM) (Picotti & Aebersold, 2012; Carr et al,
2014; Ebhardt et al, 2015). For each protein, a set of suitable
peptides is selected and their elution and fragmentation behavior is
assessed to define an MRM assay. During analysis, the mass spec-
trometer is programmed to continuously fragment only these
peptides as they elute. By monitoring several fragments per peptide,
sensitive and specific quantification can be achieved even with
low-resolution mass spectrometers. The advantage of MRM over
shotgun proteomics for verification is its higher sensitivity and
throughput. Inter-laboratory studies have achieved good repro-
ducibility (Addona et al, 2009; Abbatiello et al, 2015), but reported
sensitivities typically do not reach the low ng/ml concentration
range and practically achieved multiplexing capabilities are limited
to dozens of peptides (Percy et al, 2013; Shi et al, 2013; Oberbach
et al, 2014; Wu et al, 2015). Nevertheless, two recent studies have
reported the targeting of 82 and 192 proteins, respectively (Ozcan
et al, 2017; Percy et al, 2017). The sensitivity of MRM can be
improved to the low ng/ml or even high pg/ml ranges by more
extensive sample preprocessing with depletion or fractionation
(Burgess et al, 2014; Kim et al, 2015; Nie et al, 2017).
Absolute and accurate quantification requires internal standards
—generally heavy isotope versions of the monitored peptides.
Synthesized heavy peptides are added after digestion, creating a
source of quantitative inaccuracy since the variability of protein
digestion is not taken into account. This can be addressed by
embedding the peptide in its original sequence context, for instance,
in the SILAC-PrEST strategy, in which a 150- to 250-amino acid
stretch of each protein of interest, fused to a quantification tag, is
recombinant expressed in a heavy form (Zeiler et al, 2012; Edfors
et al, 2014; Geyer et al, 2016a).
Targeted methods can also be combined with immuno-
enrichment of proteins or peptides. For instance, in “stable isotope
standards and capture by anti-peptide antibodies” (SISCAPA) specific
peptides are immunoprecipitated together with their heavy-labeled
counterparts, followed by rapid MS-based readout (Anderson et al,
2004; Razavi et al, 2016). This combines the enrichment capabilities
of antibodies with the specificity of MS detection; however, develop-
ment of assays can be difficult and time-consuming—narrowing the
advantage compared to purely antibody-based methods.
The final phase in the triangular strategy is the validation with
immunoassays, a field that has matured over decades. For maxi-
mum specificity, sandwich assays are typically preferred (Fig 3D).
While they are costly and laborious to develop, they can achieve
ª 2017 The Authors Molecular Systems Biology 13: 942 | 2017
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high sensitivity and high throughput. Even cohorts with thousands
of participants can be tested with this technology, but only for one
or a few candidate biomarkers. Such large numbers may be neces-
sary to establish specificity not only against controls but also with
respect to other diseases. Standard requirements include insuring
adequate statistical power and replication in an independent popula-
tion. Today, such clinical studies can be expensive multi-year
endeavors, partly explaining the paucity of new biomarkers.
Immunoassays have some inherent limitations, mostly related
to antigen-antibody recognition. These include cross-reactivity,
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Figure 3. Current paradigms in plasma biomarker research (“triangular approach”).
(A) A relatively small number of cases and controls are analyzed by hypothesis-free discovery proteomics in great depth, ideally leading to the quantification of
thousands of proteins (top layer in the panel). This may yield tens of candidates with differential expression that are screened by targeted proteomics methods in cohorts of
moderate size (middle layer). Finally, for one or a few of the remaining candidates, immunoassays are developed, which are then validates in large cohorts and applied
in the clinic (bottom layer). (B) Workflow for hypothesis-free discovery proteomics. (C) Targeted proteomics for candidate verification. (D) Development of immunoassays for
clinical validation and application.
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interference by background molecules such as triglycerides, and
non-linear response (“hook effect”) (Hoofnagle & Wener, 2009;
Wild, 2013). Furthermore, not all clinically important protein vari-
ants are easily recognizable by antibody-based assays. Given these
limitations, MS-based methods would be attractive alternatives in at
least some large-scale clinical trials, but this requires much more
robust, sensitive, and higher throughput technologies than those
available today.
Over the last decade, the proteomics community has developed
guidelines for proper development of biomarkers that discuss qual-
ity standards and emphasize the importance of selecting adequate
cohorts that ensure statistical significance of the findings as well as
specificity of potential biomarkers and their potential clinical appli-
cation (Luque-Garcia & Neubert, 2007; Paulovich et al, 2008;
Mischak et al, 2010; Surinova et al, 2011; Skates et al, 2013; Parker
& Borchers, 2014; Hoofnagle et al, 2016).
Not surprisingly in view of the rigorous requirements of the
triangular strategy, there are few, if any, reports in which it has
been applied completely and successfully. This may also partly be
due to the fact that three different technologies—shotgun proteo-
mics, targeted proteomics, and immunoassay development—are
involved. Many publications just describe the first phase or only
combine it with immunoassay verification in the same cohort
(Dataset EV1).
Among the studies with more than a few participants and with
some verification, the majority selected candidates of interest and
performed Western blotting, ELISA, or MRM assays. A representa-
tive example is the study by Zhang et al (2012) in which depleted
plasma of 10 colorectal cancer patients versus controls was labeled
with iTRAQ and fractionated, leading to the identification of 72
proteins. Among several up- or downregulated proteins, ORM2 was
followed up by ELISAs in 419 individuals. Since this protein is a part
of the innate immune system (like the other two upregulated candi-
dates), it is unlikely to be a specific cancer marker. In another study,
super-depletion, iTRAQ labeling, and fractionation identified 830
proteins in a discovery cohort of 751 patients with cardiovascular
events and controls that had been reduced to 50 pooled samples
(Juhasz et al, 2011). The known markers CRP and fibronectin were
selected from the list of candidates and found to be significantly
upregulated in the original cohort by immunoassays against these
proteins. In a heart transplantation study, analysis of depleted and
iTRAQ-labeled plasma from 26 patients at five time points before
and after surgery identified a total of more than 900 proteins (273
per individual; Cohen et al, 2013). MRM assays and ELISAs against
five medium-abundant proteins in a partially independent follow-up
cohort of 43 individuals served to develop a computational pipeline
for risk markers for organ rejection. In an approach of potential clin-
ical utility, depleted plasma from a mouse model of breast cancer
allowed the identification of more than 1,000 plasma proteins from
which 88 were selected for MRM assays in an independent verifi-
cation cohort of 80 animals (Whiteaker et al, 2011).
Rectangular biomarker strategy and plasma
proteome profiling
In the last few years, the community has substantially improved all
aspects of the workflow of MS-based proteomics. In sample
preparation, laborious, multi-stage preparation workflows have
been replaced by robust, single-vial processing with a minimum of
manipulation steps. This also helps with automation and increases
throughput. The sensitivity and sequencing speed of MS instru-
ments have improved severalfold. The entire LC-MS/MS system has
become much more robust, although this is still far from what will
be needed for routine clinical application. Finally, bioinformatic
analysis of the results is now statistically sound and straightforward
to use and increasingly enables correlation of MS results with a wide
range of other classical clinical and additional “omics” data.
Illustrating the power of cutting edge MS-based proteomics, cell
lines can now routinely be quantified to a depth of more than
10,000 different proteins in a relatively short time, sometimes even
without any fractionation (Mann et al, 2013; Richards et al, 2015;
Sharma et al, 2015; Bekker-Jensen et al, 2017).
Given this technological progress of proteomics in cell line and
tissue samples, we asked whether one could also develop a fast and
automated workflow that would quantify the plasma proteome in
depth in a large number of samples (Geyer et al, 2016a). We
reasoned that this would then enable a “rectangular strategy” in
which as many proteins as possible are measured for as many indi-
viduals and conditions as possible. In contrast to the triangular
workflow, the initial discovery cohort would be much larger, ideally
encompassing hundreds or thousands of participants, resulting in a
greater likelihood to reveal any patterns that might differentiate the
investigated groups or conditions. These larger initial numbers of
plasma proteomes would allow the discovery of statistically signifi-
cant, but small differences and changes associated with a group
of proteins. In the proposed rectangular strategy, discovery and
validation cohorts would both be measured by shotgun proteomics
in great depth. This removes the dependency of validation on
discovery, meaning that both cohorts can be analyzed together
(Fig 4A). Moreover, having separate cohorts allows unmasking
study-specific confounders. A further advantage of the rectangular
strategy is its ability to discover and validate protein patterns that
are characteristic of particular health or disease states, in addition to
single biomarker candidates, something that is unattainable with
the triangular approach.
Interestingly, an analogous change of concept has already
happened a number of years ago for genome-wide association stud-
ies (GWAS). Researchers in this field found that joint analysis of as
many samples as possible was superior to a sequential pipeline
(Skol et al, 2006). In proteomics, the obvious challenge is achieving
sufficient proteomics depth in a short time, ideally without depletion
and in a robust workflow. This goal has not been achieved at the
time of writing, but the current rate of technological improvements
promises to make it feasible in the near future. Below, we discuss
four examples of this emerging approach.
The first of these investigated a cohort of 36 monozygotic and 22
dizygotic twin pairs to determine the influence of genetic back-
ground on the levels of plasma proteins (Liu et al, 2015). The
authors established a spectral library using depleted, fractionated,
and pooled samples and measured their samples with data-
independent acquisition (DIA). A total of 232 plasma samples were
then measured with 35-min gradients in a data-independent mode,
leading to the consistent quantification of 1,904 peptides and 342
proteins. Interestingly, protein levels were often relatively stable
within individuals as compared to between individuals.
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Furthermore, there were clear indications for the levels of some
proteins to be under genetic control. For instance, processes
connected to “immune response” and “blood coagulation” tended to
be heritable, whereas those associated with “hormone response”
did not. Although a pioneering study, the number of plasma
proteomes analyzed was relatively small in view of the generality of
the research question posed. Generally, genetics studies routinely
investigate thousands of participants to tease out subtle heritable
effects, illustrating the need for much higher throughput in clinical
proteomics.
Malmstro¨m et al (2016) induced sepsis in mice by injecting
S. pyogenes and followed their plasma proteomes through three time
points on non-depleted, non-fractionated samples. A library of diverse
mouse tissues was employed to support data-independent identifi-
cations as well as to determine the origin of tissue damage proteins.
In this way, 2-h runs quantified an average of 786 mouse proteins,
although it should be noted that proper FDR criteria for inferring
peptide identities in the complex DIA MS/MS spectra are still being
discussed (Nesvizhskii et al, 2007; Bruderer et al, 2017; Rosenberger
et al, 2017). Several expected categories of plasma proteins increased
during sepsis, as well as some markers associated with damage to the
vascular system. Some of the changes were related to mobilization of
the immune system against the pathogen, and others appeared to be
correlated with necrosis in severely affected animals.
In a workflow termed “plasma proteome profiling”, we focused
on the rapid and robust analysis of only 1 ll of undepleted plasma
from a single fingerpick (Geyer et al, 2016a). Total gradient time
was only 20 min, enabling extensive investigation of analytical,
intra-assay, intra-individual, and inter-individual variation of the
plasma proteome. Based on the quantification of 300 plasma
proteins, about 50 FDA-approved biomarkers were covered with
label-free quantification (CV < 20%). Rapid analysis of a wide range
of samples also revealed different sets of quality markers that clearly
classified samples with evidence of red blood cell lysis, those with
partial activation of the coagulation cascade due to inappropriate
sample handling, and those with exogenous contaminations such as
keratins. Even though this study provided a useful overview of the
information content of the plasma proteome, the depth of coverage
was not yet sufficient to address low-level, regulatory plasma
proteins. A single step of fractionation yielded a quantitative plasma
proteome of about 1,000 proteins, including 183 proteins with a
reported concentration of < 10 ng/ml, however at the cost of longer
measurement times per sample.
An improved version of the plasma proteome profiling workflow
allowed the robotic preparation and measurement of nearly 1,300
plasma proteome samples in a weight loss study (Geyer et al,
2016b). Quadruplicate analysis of individuals captured the dynamics
of an average of 437 proteins upon losing weight and over a year of
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Figure 4. Rectangular workflow.
(A) A large cohort is investigated in the discovery phase with as much proteome coverage as possible. In the validation phase, another cohort is analyzed to confirm the
biomarker candidates, but it uses the same technology and similar cohort size. Both cohorts can be analyzed in parallel, but only the proteins that are statistically significantly
different in both studies (orange as opposed to green circle in the right-hand part of panel A) are validated biomarkers. (B) Plasma proteome profiling of diverse lifestyle,
disease, treatment, or other relevant alterations will over time build up a knowledge base that connects plasma protein changes to perturbations in a general manner (upper
panel). The plasma proteome profile of a given individual can then be deconvoluted using the information and algorithms associated with the knowledge base (lower panel).
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weight maintenance. Weight loss itself had a broad effect on the
human plasma proteome with 93 significantly changed proteins.
Quantitative differences were often small but physiologically mean-
ingful, such as a 16% reduction of the adipocyte-secreted factor
SERPINF1. The longitudinal study design in which the individuals
sustained an average 12% weight loss for 1 year allowed capturing
the long-term dynamics of the plasma proteome and categorizing it
into proteins stable within versus between individuals. Multi-protein
patterns reflected the lipid homeostasis system (apolipoprotein
family), low-level inflammation, and insulin resistance. These
patterns quantified the benefits of weight loss at the level of the
individual, potentially opening up for individualized treatment and
lifestyle recommendations.
Together, these studies also highlight the advantages of longitu-
dinal over cross-sectional study designs, because the plasma
proteome tends to be much more constant within an individual over
time than between different individuals. Furthermore, they are simi-
lar in that they use less bias-prone undepleted plasma, and identify
many proteins in a given analysis time (up to 20 proteins/min).
Regarding the question of how many proteins should be covered,
we found that a proteomic depth of more than 1,500 proteins in
undepleted plasma allows the coverage of tissue leakage proteins
such as liver-based lipoprotein receptors and is within reach of tech-
nological capabilities that are currently being developed. Among the
first 300 highest abundant proteins, every fourth protein is a
biomarker, whereas in the next 1,200 proteins, it is only every 25th
protein (Fig 5). As there is no a priori reason that biomarkers should
have a skewed abundance distribution, this suggests that many
biomarkers are still to be found. We believe that the real promise of
plasma proteome profiling using the rectangular strategy is that it can
discover proteins and protein patterns that have not been considered
as biomarkers yet. The exponential increase in the underlying LC-
MS/MS technology will stimulate a matching increase in the number
of plasma proteome datasets recorded in laboratories around the
world. This will create an extensive database of plasma proteomes
and their dynamics, involving many clinical studies and individuals.
Such data could then be aggregated to build up a knowledge base
that connects proteome states to a wide diversity of “perturbations”,
including diseases, risks, treatments, and lifestyles. At a minimum,
this approach will reveal all the different conditions in which a given
set of biomarkers is involved, in addition to the specific context
where they were discovered. Proteome overlap between disease
conditions could reveal commonalities between them (Fig 4B, upper
panel). An individual’s plasma proteome profile and its dynamics
could then be interpreted by comparing it to the global knowledge
base. This could be used to deconvolute co-morbidities and to guide
treatment and monitor effectiveness (Fig 4B, lower panel).
Standardization of the proteomic biomarker
discovery pipeline
It has been suggested that the current lack of biomarkers making
their way into the market may be the result of various technical,
scientific, and political aspects including undervaluation, resulting
from inconsistent regulatory standards, and lack of evidence for
analytical validity and clinical utility (Hayes et al, 2013). To over-
come these challenges, systematic pipelines for biomarker
development have been advocated (Pavlou et al, 2013; Duffy et al,
2015). In the context of moving from a triangular to a rectangular
strategy of biomarker discovery, it will be particularly important to
consider the following principles.
(1) Analytical performance characteristics: Analytical validity is
the capacity of a test to provide an accurate and reliable measure-
ment of a biomarker. Establishment of analytical validity of the
plasma proteomics methodology will be key, because the same
method will often be carried on from discovery to application.
Detailed standards to determine analytical validity have been devel-
oped by the Clinical and Laboratory Standards Institute (CLSI)
(www.clsi.org). An overview can be found in Grant and Hoofnagle
(2014) and Jennings et al (2009). Some of these standards have
been recognized by the U.S. Food and Drug Administration (FDA)
and are accepted for bringing in vitro diagnostic test to the market
(https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfstandards/
search.cfm). Even though starting off with a full analytical valida-
tion conforming to FDA standards might be prohibitive in biomarker
discovery, at least some of the key criteria, such as carryover, accu-
racy, precision, analytical sensitivity, analytical specificity, and limit
of quantification, should be tested early on. This is in line with what
we advocate in the context of the rectangular strategy and is also
in the interest of saving resources, because the step following
biomarker discovery is biomarker validation, where analytical
validity will be mandatory.
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Figure 5. Biomarker distribution across the abundance range.
The blue area illustrates the percentage of biomarker (BM) as a function of
increasing depth of the plasma proteome. Within the 300 most abundant
proteins, 23% are already known biomarkers. The top of the yellow region
extrapolates this proportion to the remainder of the plasma proteome. If the
portion of biomarkers remained as high as it is in the 300 most abundant
proteins, there are at least 233 potential biomarkers to be discovered (yellow area
of the figure).
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(2) Clinical performance characteristics: Clinical validity relates
to the associated diseases and clinical conditions of patients and is
different from analytical validity, which focuses on the correct
measurement of analytes targeted by the assay. According to Inter-
national Standard Organization (ISO) 15189 and ISO 17025, valida-
tion is the “confirmation, through the provision of objective
evidence, that the requirements for a specific intended use or appli-
cation have been fulfilled”. Therefore, establishing clinical perfor-
mance is the main goal in the validation phase of a biomarker.
Clinical performance characteristics include (i) defining normal
reference ranges by measuring cohorts of apparently healthy indi-
viduals, (ii) determining clinical sensitivity, which is defined as the
proportion of individuals who have the disease and are tested posi-
tive, and (iii) determining clinical specificity, which is defined as the
proportion of disease-free individuals who are tested negative.
Derived statistics such as receiver operating characteristic (ROC)
plots are particularly helpful in assessing the clinical performance of
biomarkers (Zweig & Campbell, 1993; Obuchowski et al, 2004).
(3) Study design and pre-analytics: Careful study design and
well-controlled pre-analytical conditions are key requirements at
any time during a biomarker study. With respect to study design, it
is mandatory to clearly define the clinical question and the medical
need that should be addressed by the biomarker. A common prob-
lem in biomarker studies is that samples from cases and controls
have been collected independently and are mismatched for age,
ethnicity, sex, and other factors that may or may not lead to unin-
tentional bias (Duffy et al, 2015). Methods against bias include
proper study design as well as precise and deep clinical phenotyping
of participants, using systematic classifications such as the Interna-
tional Statistical Classification of Diseases (http://apps.who.int/clas
sifications/icd10/browse/2016/en) or the human phenome ontology
(Kohler et al, 2017). In this way, if a person has multiple disease
conditions, this can be properly accounted for. Sample collection is
important as well, and it is imperative that all samples (including
cases and controls) are treated equally from blood drawing to the
analytical phase. Another critical step in many biomarker studies is
biobanking. When employing ELISAs, we have found that storage of
protein-based biomarkers for 3 months requires temperatures of
80°C or below (Zander et al, 2014). Sample stability for longer
periods is only poorly investigated. However, in our experience,
shotgun proteomics has a high tolerance for variation in sample
history, because there are no protein epitopes that need to be
preserved and even partial protein degradation may be tolerable as
long as the majority of subsequently generated proteolytic peptides
remain unaltered.
The road to clinical application
The current progress in plasma proteomics opens exciting novel
avenues for research and the clinic. How likely is it, given all the
aforementioned precautions that the outlined approaches will lead
to the discovery of novel protein-based biomarkers? And what will
the proteomic biomarker of the future look like? A key theme in this
context is the discriminative power of a biomarker to distinguish
between the presence and absence of a particular disease state or
risk, in other words its clinical performance. Examples of currently
used biomarkers with high specificity and high sensitivity are
cardiac troponins, which are structural proteins specifically
expressed in cardiomyocytes and therefore highly specific for
myocardial damage. For this reason, cardiac troponins have even
been incorporated into the universal definition of myocardial infarc-
tion (Roffi et al, 2016).
It is likely that proteomics approaches will succeed in the identifi-
cation of additional biomarkers with similar performance, at least
for certain diseases. In fact, we need to be aware that most biomark-
ers used today are either highly abundant or originate from a known
pathophysiological context. As a thought experiment, we have
extrapolated the ratio of the number of biomarkers relative to the
number of proteins in the high abundance range to lower abundance
protein range, which indicates the potential for several hundred
novel biomarkers, which might be accessible with appropriate tech-
nology (Fig 5). In analogy to GWAS, where a significant number of
hits turned out to be related to previously unknown pathophysiol-
ogy of the investigated disease (Holdt & Teupser, 2013; Manolio,
2013), it is quite likely that new markers, which have hidden below
the radar of previous strategies, will be identified by novel system-
atic proteomics approaches. These biomarkers may also have the
potential to improve our understanding of disease pathophysiology
not only in diagnostics but also for therapy. Note, however, that the
identified biomarkers might not always be directly involved in the
disease pathophysiology but may only be associated with it.
The human genome encodes for about 20,000 protein coding
genes, which is opposed to more than 14,500 diseases classified by
an ICD code. This makes it even conceptually difficult to imagine that
one gene or protein is associated with each disease condition, as is
often implied in current efforts to find biomarkers. In contrast, the
rectangular strategy, allowing to screen large cohorts for multiple
markers, holds great promise to discover and validate protein
patterns that are characteristic of particular health or disease states.
Indeed, multi-marker combinations may achieve higher specificity
and sensitivity compared to single markers and first tools for select-
ing accurate marker combinations out of omics data have been devel-
oped (Mazzara et al, 2017). However, a common problem with new
biomarkers combined with existing ones is that they frequently only
lead to minor classification improvements, in particular when added
to well-performing ones (Pencina et al, 2010). Contrary to common
and intuitive assumptions, it has been shown that correlation (espe-
cially negative correlation) between predictors can be beneficial for
discrimination (Demler et al, 2013). More research in this area is
clearly warranted, and new proteomics technologies will provide the
data required for the validation of appropriate statistical methods.
Finally, how will these markers be applicable in a clinical
setting? We favor in-depth measurement of the entire plasma
proteome regardless of the occasion, as this provides the most
complete information. Over time, it adds to the longitudinal plasma
proteome profile that could usefully be obtained even of healthy
subjects. As mentioned above, plasma protein levels tend to gener-
ally be stable but person-specific, allowing individual-specific inter-
pretation instead of population-based cutoff values. Furthermore,
co-morbidities are the rule rather than the exception in many patient
groups. These are much more easily and economically addressed by
a generic diagnostic test such as plasma proteomic profiling rather
than a succession of individual ELISA tests. Nevertheless, there
would clearly be many situations in which a universal test will not
be appropriate because it may inadvertently uncover other
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conditions. Similar issues arise with other technologies such as
genome sequencing or imagining techniques, where individuals
may not want to learn about predispositions that they can do little
about. In these cases and generally to avoid the risk of overdiagno-
sis (Hofmann & Welch, 2017), clinicians may prefer plasma proteo-
mics tests of a more directed nature that focuses on a particular
disease context. This could be accomplished by the above-
mentioned MS techniques targeting a panel of proteins, rather than
the entire proteome.
For either whole-proteome diagnostic tests or panel-based tests,
the question arises how doctors would deal with the resulting multi-
dimensional data. Figure 6A shows the current single/oligo
biomarker diagnostics, which is integrated into decision-making
largely based on clinical knowledge and intuition. New biomarkers
clearly hold the promise of better informed clinical decisions, but
also imply the risk of generating patterns exceeding the human
cognitive capacity of interpretation (Fig 6B). A solution to this prob-
lem might be the algorithmic combination of multiple biomarkers
into a quantitative panel, possibly combined with clinical metadata,
which might substantially aid clinical decision-making (Fig 6C).
Given rapid developments in “deep learning” and “big data”, it will
be very interesting to see whether this combination can provide
powerful and unprecedented associations. We note that there are
already multi-parameter scores in clinical practice today. For
instance, the Child–Pugh score and the Framingham Risk Score
have each combined several blood values with patient data, to aid
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Figure 6. Implementation of proteomic data in clinical decisions.
(A) Currently, physicians make treatment decisions on the basis of a few plasma biomarker tests, combined with patient history and clinical data (upper panel). (B) Adding new
biomarkers would quickly overwhelm the current paradigm—leading to suboptimal clinical decisions. (C) Multi-protein panels and the data from past studies (the
knowledge base in Fig 4B) are combined algorithmically. This will aid the physician in making more precise recommendations for treatment, while still taking patient history
and other clinical data into account.
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clinician’s decision in treating liver disease and cardiovascular treat-
ment, respectively, for decades. This also suggests a way how
plasma proteomics could be accepted into evidence-based medical
practice, a huge challenge given the many parameters and parame-
ter combinations involved, which clearly cannot all be validated
with separate clinical trials. A pragmatic alternative might be to
devise trials in which doctors randomly obtain the proteomic infor-
mation and associated decision support. It would then be straight-
forward to determine whether there is a significant benefit in patient
outcomes.
Conclusions
Staking stock of the current practice in laboratory medicine shows
that the majority of treatment decisions are made on the basis of
blood tests and that protein measurements are even today the most
prominent among them. Despite successfully being carried out by
the millions every year, these assays are almost always directed
against individual proteins and the pace of introduction of new
protein tests has slowed to a trickle.
MS-based proteomics clearly has the potential for multiplexed
and highly specific measurements, in which protein patterns rather
than single biomarkers could be the relevant readout. Our review of
the literature revealed that past efforts were held back by the great
analytical challenges of the plasma proteome, something that is only
now giving way to exciting technological developments. We argue
that the analysis of large numbers of conditions and participants in
all stages of the discovery and validation process has the potential
to produce biomarker panels that are likely to be of clinical value.
When coupled to large knowledge bases of changes in protein
patterns in defined conditions, such a plasma proteome profiling
strategy could in principle exploit the entire information contents of
this body fluid.
To make this vision a reality, further improvements in through-
put, depth of proteome coverage, robustness, and accessibility of
the underlying workflow are crucial. Furthermore, plasma proteo-
mics can also be extended to the analysis of post-translation modifi-
cations. Likewise, plasma metabolomics also uses MS-based
workflows and could routinely be integrated with plasma proteo-
mics in the future. We are confident that the required technological
developments can and will all be achieved over time. At least as
much of a challenge will be conceptual and “political”, as the
proteomic information deluge needs to be turned into actionable
data for the physician and the healthcare system. This will require a
dedicated and untiring commitment from all partners involved. We
believe that the promise of much more precise and specific diagnos-
tics will amply reward such efforts.
Expanded View for this article is available online.
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